We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Neoadjuvant Camrelizumab for Non-Small Cell Lung Cancer: A Retrospective Multicenter, Real-World Study (CTONG2004).
- Authors
Liu, Si-Yang; Chen, Qixun; Zhou, Chengzhi; Zhang, Huizhong; Li, Wen; Chen, Jianhua; Hu, Jian; Wu, Lin; Chen, Qunqing; Dai, Qiangsheng; Shan, Jian-Zhen; Xu, Fei; Liu, Si-Yang Maggie; Wu, Yi-Long
- Abstract
Background: Camrelizumab has shown encouraging efficacy in advanced non-small cell lung cancer (NSCLC), either as monotherapy or combined with chemotherapy. However, evidence of neoadjuvant camrelizumab for NSCLC remains lacking. Methods: Patients with NSCLC treated with neoadjuvant camrelizumab-based therapy followed by surgery between December 2020 and September 2021 were retrospectively reviewed. Demographic and clinical data, details of neoadjuvant therapy and surgical information were retrieved. Results: In this multicenter retrospective real-world study, 96 patients were included. Ninety-five patients (99.0%) received neoadjuvant camrelizumab combined with platinum-based chemotherapy, with a median of 2 cycles (range 1–6). The median interval from the last dose to surgery was 33 days (range 13–102 days). Seventy patients (72.9%) underwent minimally invasive surgery. Lobectomy was the most frequent surgical procedure (94 [97.9%]). The median estimated intraoperative blood loss was 100 mL (range 5–1200 mL), and the median operative time was 3.0 h (range 1.5–6.5 h). The R0 resection rate was 93.8%. Twenty-one patients (21.9%) experienced postoperative complications, with the most common being cough and pain (both 6 [6.3%]). The overall response rate was 77.1% (95% CI 67.4–85.0%), and the disease control rate was 93.8% (95% CI 86.9–97.7%). Twenty-six patients (27.1%, 95% CI 18.5–37.1%) had pathological complete response. Neoadjuvant treatment-related adverse events of grade ≥ 3 were reported in seven patients (7.3%), with the most frequent being abnormal liver enzymes (two [2.1%]). No treatment-related deaths were reported. Conclusion: The real-world data indicated that camrelizumab-based therapy had promising efficacy for NSCLC in the neoadjuvant setting, with manageable toxicities. Prospective studies investigating neoadjuvant camrelizumab are warranted.
- Subjects
NON-small-cell lung carcinoma; SURGICAL blood loss; BLOOD loss estimation; MINIMALLY invasive procedures; COUGH; ADVERSE health care events
- Publication
Cancer Immunology, Immunotherapy, 2023, Vol 72, Issue 7, p2257
- ISSN
0340-7004
- Publication type
Article
- DOI
10.1007/s00262-023-03412-8